(NASDAQ: HLVX) Hillevax's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Hillevax's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast HLVX's revenue for 2026 to be $621,260,350, with the lowest HLVX revenue forecast at $621,260,350, and the highest HLVX revenue forecast at $621,260,350. On average, 2 Wall Street analysts forecast HLVX's revenue for 2027 to be $5,469,079,113, with the lowest HLVX revenue forecast at $1,570,546,165, and the highest HLVX revenue forecast at $9,367,612,061.
In 2028, HLVX is forecast to generate $13,248,053,908 in revenue, with the lowest revenue forecast at $2,186,836,432 and the highest revenue forecast at $26,261,917,515.